Charles N. York II serves as Executive at Aeglea BioTherapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Charles N. York II has executed 63 insider transactions totaling $3.3M, demonstrating a bearish approach to their equity position. Their most recent transaction on Aug 4, 2022 involved selling 10,000 shares valued at $200.5K.
Charles N. York II currently holds 294,715 shares of Aeglea BioTherapeutics, Inc. (AGLE), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Charles N. York II has been a net seller of AGLE stock. They have purchased $116.3K and sold $3.1M worth of shares.
Charles N. York II's most recent insider trade was on Aug 4, 2022, when they sold 10,000 shares at $20.05 per share.
Get notified when new Form 4 filings are submitted
| $20.00 |
| Discretionary |
| Jul 8, 2022 | DAWN | $28.3K | Sale | 1,416 | $20.00 | Discretionary |
| Jul 5, 2022 | DAWN | $16.0K | Sale | 800 | $20.00 | Discretionary |
| Jul 1, 2022 | DAWN | $29.6K | Sale | 1,479 | $20.00 | Discretionary |
| Dec 5, 2017 | AGLE | $48.7K | Purchase | 10,241 | $4.76 | Discretionary |
| Dec 4, 2017 | AGLE | $16.2K | Purchase | 3,259 | $4.97 | Discretionary |
| Dec 1, 2017 | AGLE | $29.8K | Purchase | 6,500 | $4.59 | Discretionary |
| Aug 15, 2017 | AGLE | $4.9K | Purchase | 1,959 | $2.52 | Discretionary |
| Feb 15, 2017 | AGLE | $8.6K | Purchase | 2,000 | $4.28 | Discretionary |
| Aug 15, 2016 | AGLE | $8.0K | Purchase | 2,000 | $3.99 | Discretionary |
| Apr 12, 2016 | AGLE | $0 | Conversion | 1,324 | $N/A | Discretionary |
| Apr 12, 2016 | AGLE | $0 | Conversion | 11,560 | $N/A | Discretionary |